Dr. Jayant holds an MD certification, a Master in Hepatobiliary and Pancreatic Surgery from Imperial College London and successfully cleared his MRCS from Royal College of Surgeons Edinburgh. He has completed PhD (Medicine) from the prestigious University of Warwick. His thesis ascertained deeper insight into the clinical implications and immuno-modulatory changes following liver resection using RF-based device in liver cancer. Further, he has been awarded FACS from the American College of Surgeons. Dr. Jayant’s work at Imperial College London is assessing the clinical and immunomodulatory aspects of Radiofrequency (RF) energy in the management of Liver and Pancreatic Cancer. He is particularly interested in the development of newer techniques of pancreatic and liver cancer management. He is involved in the understanding of immunological changes following the application of liver resection device in various liver cancers, and its implication on clinical outcomes in advanced liver cancer with checkpoint inhibitors. His recent study on liver cancer. Assessing the impact and benefits of RF-assisted parenchymal sparing liver resection on post-hepatectomy and liver failure; reflects the development of the RF-assisted liver resection using the Habib-4X as a feasible and safe technique of liver resection with a low incidence of post-hepatectomy liver failure and mortality. In addition, he is also involved in the project RF-assisted pancreaticoduodenectomy for locally advanced pancreatic adenocarcinoma- A novel approach which leads to the development of newer RF-assisted pancreaticoduodenectomy technique which is more feasible and safer than a vascular resection with a conventional technique. Dr. Jayant has accrued several accolades for his contribution to medical sciences including Best Investigator Award from American College of Surgeons in 2015. Moreover, his research interest includes understanding the role of normothermic perfusion in liver transplantation and published papers and was recipient of the Young Investigator Award from Asia-Pacific Primary Liver Cancer Expert Meeting, Seoul, South Korea; and Japanese Digestive Disease Week 2018, Kobe, Japan.